CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1

被引:40
|
作者
Heredia, Alonso [1 ]
Gilliam, Bruce [1 ]
DeVico, Anthony [1 ]
Le, Nhut [1 ]
Bamba, Douty [1 ]
Flinko, Robin [1 ]
Lewis, George [1 ]
Gallo, Robert C. [1 ]
Redfield, Robert R. [1 ]
机构
[1] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA
关键词
antiretroviral therapy; fusion inhibitors; Enfuvirtide; CCR5; coreceptor;
D O I
10.1097/QAD.0b013e32815278ea
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective and design: Studies in cell lines have demonstrated that CCR5 coreceptor levels influence the replication efficiency and Enfuvirticle (T-20) susceptibility of R5 HIV-1 strains. At present, however, the role that CCR5 levels on primary CD4 T cells - which are markedly lower than in cell lines and vary only similar to fivefold among mostdonors - may play in virus replication levels or susceptibility to T-20 is not known. In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1. Methods: CD4 and CCR5 density levels were determined by Quantitative FACS analysis. Virus infectivity assays were conducted in cell lines and primary cells. Associations between coreceptor density, virus replication and T-20 sensitivity were tested using the Spearman's correlation test. Results: We found a positive correlation (r, 0.55; P = 0.011) between CCR5 density levels on primary CD4 T cells and replication of R5 HIV-1. In cell lines expressing physiologically relevant levels of CD4 and CCR5, T-20 was significantly more potent in cells with low CCR5 levels. In addition, T20 50% inhibitory concentrations for R5 HIV-1 replication varied similar to 100-fold among primary cells from different donors and they were positively correlated with CCR5 density values (r, 0.84; P=0.00004). Conclusions: These results suggest that CCR5 density levels in HIV-1 patients may impact the activity of T-20 against R5 strains and that therapeutic approaches to alter CCR5 density may potentiate T-20. (C) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1317 / 1322
页数:6
相关论文
共 50 条
  • [1] The immunomodulatory drug rapamycin potentiates the antiviral activity of the fusion inhibitor enfuvirtide (T-20) against R5 HIV-1 by reducing, CCR5 density levels on CD4 T cells
    Heredia, Alonso
    Latinovic, Olga S.
    DeVico, Anthony
    Le, Nhut
    Bamba, Douty
    Melikyan, Gregory
    Gallo, Robert C.
    Redfield, Robert R.
    [J]. BIOPHYSICAL JOURNAL, 2007, : 246A - 246A
  • [2] The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication
    Guigues, Adeline
    Gimenez, Sandrine
    Mettling, Clement
    Maurel, Damien
    Doumazane, Etienne
    Prezeau, Laurent
    Francois, Vincent
    Corbeau, Pierre
    [J]. AIDS, 2024, 38 (10) : 1449 - 1459
  • [3] Enhanced replication of R5 HIV-1 over X4 HIV-1 in CD4+CCR5+CXCR4+ T cells
    Roy, AM
    Schweighardt, B
    Eckstein, LA
    Goldsmith, MA
    McCune, JM
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) : 267 - 275
  • [4] Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression
    Butticaz, C
    Ciuffi, A
    Muñoz, MM
    Thomas, J
    Bridge, A
    Pebernard, S
    Iggo, R
    Meylan, P
    Telenti, A
    [J]. ANTIVIRAL THERAPY, 2003, 8 (05) : 373 - 377
  • [5] Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
    Heredia, Alonso
    Gilliam, Bruce
    Latinovic, Olga
    Le, Nhut
    Bamba, Douty
    DeVico, Anthony
    Melikyan, Gregory B.
    Gallo, Robert C.
    Redfield, Robert R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (07) : 2489 - 2496
  • [6] Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates
    Pesenti, E
    Pastore, C
    Lillo, F
    Siccardi, AG
    Vercelli, D
    Lopalco, L
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (11) : 983 - 987
  • [7] The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through Gαi-protein signalling
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Reant, Brigitte
    Robert-Hebmann, Veronique
    Reynes, Jacques
    Clot, Jacques
    Corbeau, Pierre
    [J]. AIDS, 2006, 20 (10) : 1369 - 1377
  • [8] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
    Nahabedian, John
    Sharma, Amit
    Kaczmarek, Maryska E.
    Wilkerson, Greg K.
    Sawyer, Sara L.
    Overbaugh, Julie
    [J]. VIROLOGY, 2017, 512 : 180 - 186
  • [9] Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection
    Lin, YL
    Mettling, C
    Portales, P
    Reynes, J
    Clot, J
    Corbeau, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) : 15590 - 15595
  • [10] CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression
    Reynes, J
    Portales, P
    Segondy, M
    Baillat, V
    André, P
    Avinens, O
    Picot, MC
    Clot, J
    Eliaou, JF
    Corbeau, P
    [J]. AIDS, 2001, 15 (13) : 1627 - 1634